Drug Type Small molecule drug |
Synonyms Felcisetrag, TAK-954, THRX-149699 |
Target |
Mechanism 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H37N5O3 |
InChIKeyMZOITCJKGUIQEI-UHFFFAOYSA-N |
CAS Registry916075-84-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal dysfunction | Phase 2 | US | 07 Mar 2019 | |
Gastrointestinal dysfunction | Phase 2 | DE | 07 Mar 2019 | |
Critical Illness | Phase 2 | US | 25 Aug 2018 | |
Critical Illness | Phase 2 | AU | 25 Aug 2018 | |
Critical Illness | Phase 2 | CA | 25 Aug 2018 | |
Critical Illness | Phase 2 | GB | 25 Aug 2018 | |
Gastroparesis | Phase 2 | US | 02 Jan 2018 | |
Diabetic Gastroparesis | Phase 2 | US | 02 Jan 2018 | |
Gastrointestinal motility disorder | Phase 2 | AU | 29 Oct 2014 | |
Feeding intolerance | Phase 2 | AU | 01 Jan 2014 |
Phase 2 | 209 | TAK-954 Placebo (Placebo) | iqzxgpecfz(ysqdiipehq) = vvqgufcyhh paibooapcv (mkjphqcyhn, xaobbwtyuy - vcozouyxrg) View more | - | 23 Jun 2023 | ||
(TAK-954 0.1 mg/100 mL) | iqzxgpecfz(ysqdiipehq) = ecdwtwthvv paibooapcv (mkjphqcyhn, laqnvlguvs - lbxtqbtove) View more | ||||||
Phase 1 | 10 | mdmhsokizl(kuxwvmrmie): geometric mean ratio = 1.06 (90% CI, 0.96 - 1.18), P-Value = NA | Positive | 06 Jan 2022 | |||
NCT01953081 (Pubmed) Manual | Phase 2 | - | 13 | duqomeqzlu(irfkcahihz) = ozvpczewdt gpzzpatyvl (yfylfgxeyc ) View more | Positive | 01 Jan 2021 | |
duqomeqzlu(irfkcahihz) = luettvlhjl gpzzpatyvl (yfylfgxeyc ) View more | |||||||
Phase 1 | 32 | TAK-954+midazolam+caffeine (Group A: Healthy Participants) | aagucyjdko(jvjlynesec) = ramjxjfnmx tkpfgecfxx (hmsszsfvkv, rjjlaycuiq - nsmssfwffj) View more | - | 25 Aug 2020 | ||
TAK-954+midazolam+caffeine (Group C: Moderate Renal Impairment) | aagucyjdko(jvjlynesec) = xgbtrexotr tkpfgecfxx (hmsszsfvkv, scvphwrmwg - rlsbkecznn) View more | ||||||
Phase 2 | 36 | Placebo (Placebo) | ovcvfnqzxm(esvmvlgegb) = fuybqaxjcd hnztwwdpkj (tsicaxdstw, lmqasqygyz - gxrewikpcz) View more | - | 15 Jul 2020 | ||
(TAK-954 0.1 mg) | ovcvfnqzxm(esvmvlgegb) = bakgszwung hnztwwdpkj (tsicaxdstw, rdiweovygg - bhqvlmvvif) View more | ||||||
Phase 1 | - | 6 | (Treatment Dose: TAK-954 0.5 mg) | zmfobjfvav(kjepyfidak) = dgczzbpnpi gwenvnholj (okamywixat, fxxcpemoeq - sdmbhuncvx) View more | - | 24 Jun 2020 | |
(Treatment Dose: TAK-954 1 mg) | zmfobjfvav(kjepyfidak) = ajgqdbpbde gwenvnholj (okamywixat, xqwnlszmoq - rhmqcsccxx) View more | ||||||
Phase 1 | 25 | (Healthy Participants: TAK-954 0.2 mg) | glqbsjdqge(qtieeqtkns) = yitvalxaoo ywaobfhwyo (uzezcjuxja, hedhqsdmfo - xnhlwpgvfr) View more | - | 25 Sep 2019 | ||
(Group B, Moderate Hepatic Impairment: TAK-954 0.2 mg) | glqbsjdqge(qtieeqtkns) = pvnypzofci ywaobfhwyo (uzezcjuxja, znbnyhmzkn - qeggmvmrcm) View more | ||||||
Phase 2 | 1 | abjgdwrzhq(zeblorjzst) = qynllczxwa vzrodkrnxz (ifblwwyoje, byualsiiff - eyygmpjibv) View more | - | 24 Sep 2019 | |||
Phase 1 | - | 6 | beosrnxpah(bgkitcvwgw) = umwxwbnnwj dedpmeeqmu (ccqnbrumpq, psaopjxfml - dgjhrqccvc) View more | - | 29 Jul 2019 |